Glycosylation is a topic of intense current interest in the development of biopharmaceuticals because it is related to drug safety and efficacy. This work describes results of an interlaboratory study on the glycosylation of the Primary Sample (PS) of NISTmAb, a monoclonal antibody reference material. Seventy-six laboratories from industry, university, research, government, and hospital sectors in Europe, North America, Asia, and Australia submitted a total of 103 reports on glycan distributions. The principal objective of this study was to report and compare results for the full range of analytical methods presently used in the glycosylation analysis of mAbs. Therefore, participation was unrestricted, with laboratories choosing their own measurement techniques. Protein glycosylation was determined in various ways, including at the level of intact mAb, protein fragments, glycopeptides, or released glycans, using a wide variety of methods for derivatization, separation, identification, and quantification. Consequently, the diversity of results was enormous, with the number of glycan compositions identified by each laboratory ranging from 4 to 48. In total, one hundred sixteen glycan compositions were reported, of which 57 compositions could be assigned consensus abundance values. These consensus medians provide community-derived values for NISTmAb PS. Agreement with the consensus medians did not depend on the specific method or laboratory type. The study provides a view of the current state-of-the-art for biologic glycosylation measurement and suggests a clear need for harmonization of glycosylation analysis methods.

Glycans play important roles in a variety of biological processes. Their activities are closely related to the fine details of their structures. Unlike the simple linear chains of proteins, branching is a unique feature of glycan structures, making their identification extremely challenging. Multistage mass spectrometry (MS n ) has become the primary method for glycan structural identification. The major difficulty for MS n is the selection of fragment ions as precursors for the next stage of scanning. Widely used strategies are either manual selection by experienced experts, which requires considerable expertise and time, or simply selecting the most intense peaks by which the product-ion spectrum generated may not be structurally informative and therefore fail to make the assignment. We here report a glycan “intelligent precursor selection” strategy (GIPS) to guide MS n experiments. Our approach consists of two key elements, an empirical model to calculate candidate glycan’s probability and a statistical model to calculate fragment ion’s distinguishing power in order to select the structurally most informative peak as the precursor for next-stage scanning. Using 15 glycan standards, including three pairs with isomeric sequences and eight variously fucosylated oligosaccharides on linear or branched hexasaccharide backbones isolated from a human milk oligosaccharide fraction by HPLC, we demonstrate its successful application to branching pattern analysis with improved efficiency and sensitivity and also the potential for automated operation.

The densely glycosylated spike (S) protein highly exposed on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) surface mediates host cell entry by binding to the receptor angiotensin-converting enzyme 2 (ACE2). However, the role of glycosylation has not been fully understood. In this study, we investigated the effect of different N -glycosylation of S1 protein on its binding to ACE2. Using real-time surface plasmon resonance assay the negative effects were demonstrated by the considerable increase of binding affinities of de- N -glycosylated S1 proteins produced from three different expression systems including baculovirus-insect, Chinese hamster ovarian and two variants of human embryonic kidney 293 cells. Molecular dynamic simulations of the S1 protein-ACE2 receptor complex revealed the steric hinderance and Coulombic repulsion effects of different types of N -glycans on the S1 protein interaction with ACE2. The results should contribute to future pathological studies of SARS-CoV-2 and therapeutic development of Covid-19, particularly using recombinant S1 proteins as models.